Special Issues

Pharmacoepidemiology publishes Special Issues to create collections of papers on specific topics, with the aim of building a community of authors and readers to discuss the latest research and develop new ideas and research directions. Special Issues are led by Guest Editors, who are experts on the topic and all Special Issue submissions follow MDPI's standard editorial process. The journal’s Editor-in-Chief and/or designated Editorial Board Member will oversee Guest Editor appointments and Special Issue proposals, checking their content for relevance and ensuring the suitability of the material for the journal. The papers published in a Special Issue will be collected and displayed on a dedicated page of the journal’s website. Further information on MDPI's Special Issue policies and Guest Editor responsibilities can be found here. For any inquiries related to a Special Issue, please contact the Editorial Office.

Search by Title/Keyword
 
Order results
Display
Results per page
Pharmacoepidemiology and Pharmacovigilance in the UK
edited by Tanja Mueller
submission deadline 30 Jun 2026 | 2 articles | Viewed by 2863 | Submission Open
Keywords: pharmacoepidemiology; drug utilisation; pharmacovigilance; drug safety; clinical effectiveness; harm and benefits; UK
Women’s Special Issue Series: Pharmacoepidemiology
edited by , Li-Chia Chen and
submission deadline 30 Jun 2026 | 1 articles | Viewed by 2055 | Submission Open
Keywords: pharmacoepidemiology; pharmacovigilance; preventative pharmacovigilance; ecopharmacovigilance; patient safety; patterns in drug utilization; polypharmacology; randomized controlled drug trials; post-marketing surveillance; pharmacoeconomics
Recent Advances in the Pharmacoepidemiology of Antirheumatic Medication
edited by Roberta Foti, Beatrice Maranini and Veronica Venturelli
submission deadline 30 Jun 2026 | Viewed by 818 | Submission Open
Keywords: antirheumatic medication; rheumatoid arthritis (RA); psoriatic arthritis (PsA); systemic lupus erythematosus (SLE); csDMARDs; bDMARDs; JAK inhibitors; anti-TNFα ; retention rate; safety
Back to TopTop